DURING the past two years, 13 patients with purulent meningitis have been treated with bacitracin. The organisms and their incidence were as follows: Staphylococcus, six cases; Streptococcus, two cases; Pneumococcus, one case; mixed organisms, two cases, and an unidentified gram-positive coccus, two cases (table 1).
Of the group of six patients with staphylococcic meningitis, five are reported on in a separate article.1 All these 6 patients were treated with bacitracin by the intrathecal or the intraventricular route, or by both routes whenever such a method was indicated. This therapy was supplemented by the intramuscular injection of bacitracin and other antibiotics when that seemed advisable. In every instance the causal organism was found to be resistant to penicillin, which, in fact, had previously been used in excessive amounts both by subarachnoid and by intramuscular injections, with no avail. After bacitracin therapy five patients recovered and one died. The
TENG P. FURTHER EXPERIENCES IN TREATMENT OF SEPTIC MENINGITIS WITH BACITRACIN. AMA Arch NeurPsych. 1950;64(6):861–877. doi:10.1001/archneurpsyc.1950.02310300108010
Customize your JAMA Network experience by selecting one or more topics from the list below.